Connor Clark & Lunn Investment Management Ltd. Buys Shares of 91,449 Celcuity, Inc. $CELC

Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Celcuity, Inc. (NASDAQ:CELC) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund purchased 91,449 shares of the company’s stock, valued at approximately $9,567,000. Connor Clark & Lunn Investment Management Ltd. owned 0.19% of Celcuity at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of CELC. PNC Financial Services Group Inc. lifted its holdings in Celcuity by 20.1% in the first quarter. PNC Financial Services Group Inc. now owns 514 shares of the company’s stock valued at $59,000 after buying an additional 86 shares during the period. EverSource Wealth Advisors LLC grew its holdings in Celcuity by 15.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 944 shares of the company’s stock worth $99,000 after acquiring an additional 124 shares during the period. US Bancorp DE raised its position in shares of Celcuity by 25.4% during the 3rd quarter. US Bancorp DE now owns 706 shares of the company’s stock valued at $35,000 after acquiring an additional 143 shares during the last quarter. Intech Investment Management LLC raised its position in shares of Celcuity by 1.4% during the 4th quarter. Intech Investment Management LLC now owns 12,983 shares of the company’s stock valued at $1,295,000 after acquiring an additional 183 shares during the last quarter. Finally, Aristides Capital LLC lifted its stake in shares of Celcuity by 2.0% in the 4th quarter. Aristides Capital LLC now owns 15,303 shares of the company’s stock valued at $1,526,000 after purchasing an additional 303 shares during the period. 63.33% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on CELC. Craig Hallum reaffirmed a “buy” rating and set a $178.00 price objective on shares of Celcuity in a research note on Wednesday, July 15th. Citigroup reissued a “market outperform” rating on shares of Celcuity in a research note on Monday, August 17th. Wall Street Zen cut Celcuity from a “sell” rating to a “strong sell” rating in a report on Saturday, August 15th. Wells Fargo & Company decreased their target price on Celcuity from $183.00 to $166.00 and set an “overweight” rating for the company in a research report on Wednesday, June 3rd. Finally, Stifel Nicolaus lowered their price target on Celcuity from $175.00 to $150.00 and set a “buy” rating for the company in a research note on Friday, August 14th. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $154.55.

Celcuity Trading Up 3.0%

Shares of NASDAQ CELC opened at $95.08 on Thursday. Celcuity, Inc. has a twelve month low of $44.42 and a twelve month high of $151.02. The stock has a market cap of $4.65 billion, a price-to-earnings ratio of -22.11 and a beta of 0.20. The company has a quick ratio of 8.93, a current ratio of 8.93 and a debt-to-equity ratio of 6.04. The company’s fifty day moving average is $94.52 and its 200-day moving average is $107.38.

Celcuity (NASDAQ:CELC) last released its quarterly earnings data on Thursday, August 13th. The company reported ($1.44) EPS for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.28). Equities research analysts predict that Celcuity, Inc. will post -4.75 EPS for the current year.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.